Gilead Sciences, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2019 | $39.10B | $61.63B | $11.63B |
| FY2020 | $50.21B | $68.41B | $6.00B |
| FY2021 | $46.88B | $67.95B | $5.34B |
| FY2022 | $41.93B | $63.17B | $5.41B |
| FY2023 | $39.29B | $62.13B | $6.09B |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2019 | $39.10B | $61.63B | $11.63B |
| FY2020 | $50.21B | $68.41B | $6.00B |
| FY2021 | $46.88B | $67.95B | $5.34B |
| FY2022 | $41.93B | $63.17B | $5.41B |
| FY2023 | $39.29B | $62.13B | $6.09B |